Breaking News, Collaborations & Alliances

Ionis, AstraZeneca Partner to Develop and Commercialize Eplontersen

Will develop a global strategy for developing, manufacturing and commercializing eplontersen, an antisense medicine to treat transthyretin amyloidosis.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ionis Pharmaceuticals, a leader in RNA-targeted therapies, entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ investigational antisense medicine for the treatment of transthyretin amyloidosis (ATTR).   Ionis will receive $200 million upfront, up to $485 million in development and approval milestones, and up to $2.9 billion in milestone payments, as well as royalties.   Eplontersen, formerly known as IONIS-TTR-LRx, is desig...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters